-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cerebral Infarction (Brain Infarction) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cerebral Infarction (Brain Infarction) - Drugs In Development, 2023’, provides an overview of the Cerebral Infarction (Brain Infarction) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cerebral Infarction (Brain Infarction), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Brain Derived Neurotrophic Factor – Drugs In Development, 2023
Global Markets Direct’s Brain Derived Neurotrophic Factor provides in depth analysis on Brain Derived Neurotrophic Factor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Brain Derived Neurotrophic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vociprotafib in Brain Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vociprotafib in Brain Cancer Drug Details: Vociprotafib is under development for the treatment of relapsed/refractory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Metastatic Brain Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Metastatic Brain Tumor Drug Details: Palbociclib (Ibrance, Agatha) is a pyridopyrimidine-derived cyclin-dependent kinase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Metastatic Brain Tumor Drug Details: GLR-2007 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WSD-0922 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WSD-0922 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WSD-0922 in Metastatic Brain Tumor Drug Details: WSD-0922 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-22P in Refractory Brain Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-22P in Refractory Brain Metastasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-22P in Refractory Brain Metastasis Drug Details: SL-22P is under...
-
Product Insights
Likelihood of Approval Analysis for Ischemic Stroke
Overview How likely is it that the drugs in Ischemic Stroke will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ischemic Stroke Overview Ischemic stroke occurs when there is a disruption of...